Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Pro... von Beer, Tomasz M, Kwon, Eugene D, Drake, Charles G, Fizazi, Karim, Logothetis, Christopher, Gravis, Gwenaelle, Ganju, Vinod, Polikoff, Jonathan, Saad, Fred, Humanski, Piotr, Piulats, Josep M, Gonzalez Mella, Pablo, Ng, Siobhan S, Jaeger, Dirk, Parnis, Francis X, Franke, Fabio A, Puente, Javier, Carvajal, Roman, Sengeløv, Lisa, McHenry, M Brent, Varma, Arvind, van den Eertwegh, Alfonsus J, Gerritsen, Winald

Volltext

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multic... von Kwon, Eugene D, Prof, Drake, Charles G, MD, Scher, Howard I, Prof, Fizazi, Karim, Prof, Bossi, Alberto, MD, van den Eertwegh, Alfons J M, MD, Krainer, Michael, MD, Houede, Nadine, MD, Santos, Ricardo, MD, Mahammedi, Hakim, MD, Ng, Siobhan, MD, Maio, Michele, MD, Franke, Fabio A, MD, Sundar, Santhanam, MBBS, Agarwal, Neeraj, MD, Bergman, Andries M, MD, Ciuleanu, Tudor E, Prof, Korbenfeld, Ernesto, MD, Sengeløv, Lisa, MD, Hansen, Steinbjorn, MD, Logothetis, Christopher, Prof, Beer, Tomasz M, Prof, McHenry, M Brent, PhD, Gagnier, Paul, MD, Liu, David, MD, Gerritsen, Winald R, Prof

Volltext

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long... von Fizazi, Karim, Drake, Charles G., Beer, Tomasz M., Kwon, Eugene D., Scher, Howard I., Gerritsen, Winald R., Bossi, Alberto, den Eertwegh, Alfons J.M. van, Krainer, Michael, Houede, Nadine, Santos, Ricardo, Mahammedi, Hakim, Ng, Siobhan, Danielli, Riccardo, Franke, Fabio A., Sundar, Santhanam, Agarwal, Neeraj, Bergman, André M., Ciuleanu, Tudor E., Korbenfeld, Ernesto, Sengeløv, Lisa, Hansen, Steinbjorn, McHenry, M. Brent, Chen, Allen, Logothetis, Christopher

Volltext

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial von Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y, McJannett, Margaret M, Stockler, Martin R, Violet, John A, Williams, Scott G, Martin, Andrew J, Davis, Ian D, Azad, Arun A, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Ng, Siobhan, Pattison, David A, Ramdave, Shakher, Rana, Nisha, Redfern, Andrew D, Rutherford, Natalie K, Sandhu, Shahneen, Scott, Andrew M, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Violet, John A, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, Zhang, Alison Y

Volltext

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer von Hussain, Maha, Mateo, Joaquin, Fizazi, Karim, Saad, Fred, Shore, Neal, Sandhu, Shahneen, Chi, Kim N, Sartor, Oliver, Agarwal, Neeraj, Olmos, David, Thiery-Vuillemin, Antoine, Twardowski, Przemyslaw, Roubaud, Guilhem, Özgüroğlu, Mustafa, Kang, Jinyu, Burgents, Joseph, Gresty, Christopher, Corcoran, Claire, Adelman, Carrie A, de Bono, Johann

Volltext

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer von Gulley, James L, Borre, Michael, Vogelzang, Nicholas J, Ng, Siobhan, Agarwal, Neeraj, Parker, Chris C, Pook, David W, Rathenborg, Per, Flaig, Thomas W, Carles, Joan, Saad, Fred, Shore, Neal D, Chen, Liddy, Heery, Christopher R, Gerritsen, Winald R, Priou, Frank, Langkilde, Niels C, Novikov, Andrey, Kantoff, Philip W

Volltext

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer von Chi, Kim N, Rathkopf, Dana, Smith, Matthew R, Efstathiou, Eleni, Attard, Gerhardt, Olmos, David, Lee, Ji Youl, Small, Eric J, Pereira de Santana Gomes, Andrea J, Roubaud, Guilhem, Saad, Marniza, Zurawski, Bogdan, Sakalo, Valerii, Mason, Gary E, Francis, Peter, Wang, George, Wu, Daphne, Diorio, Brooke, Lopez-Gitlitz, Angela, Sandhu, Shahneen

Volltext

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The... von Hammel, Pascal, Huguet, Florence, van Laethem, Jean-Luc, Goldstein, David, Glimelius, Bengt, Artru, Pascal, Borbath, Ivan, Bouché, Olivier, Shannon, Jenny, André, Thierry, Mineur, Laurent, Chibaudel, Benoist, Bonnetain, Franck, Louvet, Christophe

Volltext

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a bio... von Buteau, James P, Martin, Andrew J, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen, Joshua, Anthony M, Francis, Roslyn J, Zhang, Alison Y, Scott, Andrew M, Lee, Sze-Ting, Azad, Arun A, McJannett, Margaret M, Stockler, Martin R, Williams, Scott G, Davis, Ian D, Hofman, Michael S, Akhurst, Tim, Alipour, Ramin, Azad, Arun A, Banks, Patricia, Beaulieu, Alexis, Buteau, James P, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Kong, Grace, Kwan, Edmond M, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lewin, Jeremy, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Moodie, Kate, Murphy, Declan G, Ng, Siobhan, Pattison, David A, Pokorski, Izabella, Ramdave, Shakher, Ravi Kumar, Aravind S, Redfern, Andrew D, Rutherford, Natalie K, Saghebi, Javad, Sandhu, Shahneen, Scott, Andrew M, Spain, Lavinia, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Thang, Sue Ping, Tran, Ben, Wallace, Roslyn, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, Zhang, Alison Y

Volltext

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy von Ryan, Charles J, Smith, Matthew R, de Bono, Johann S, Molina, Arturo, Logothetis, Christopher J, de Souza, Paul, Fizazi, Karim, Mainwaring, Paul, Piulats, Josep M, Ng, Siobhan, Carles, Joan, Mulders, Peter F.A, Basch, Ethan, Small, Eric J, Saad, Fred, Schrijvers, Dirk, Van Poppel, Hendrik, Mukherjee, Som D, Suttmann, Henrik, Gerritsen, Winald R, Flaig, Thomas W, George, Daniel J, Yu, Evan Y, Efstathiou, Eleni, Pantuck, Allan, Winquist, Eric, Higano, Celestia S, Taplin, Mary-Ellen, Park, Youn, Kheoh, Thian, Griffin, Thomas, Scher, Howard I, Rathkopf, Dana E

Volltext

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, do... von Petrylak, Daniel P, de Wit, Ronald, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Hegemann, Miriam, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Tortora, Giampaolo, Safina, Sufia, Rodriguez-Vida, Alejo, Harputluoglu, Hakan, Widau, Ryan C, Liepa, Astra M, Hamid, Oday, Zimmermann, Annamaria H, Bell-McGuinn, Katherine M, Wong, Suet-Lai Shirley, Hovey, Elizabeth Jane, Ng, Siobhan Su Wan, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Jensen, Niels Viggo, Laguerre, Brigitte, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Grimm, Marc-Oliver, Gakis, Georgios, Schultze-Seemann, Wolfgang, Mavroudis, Dimitrios, Révész, Janos, Geczi, Lajos, Rosenbaum, Eli, Kejzman, Daniel, Peer, Avivit, Sarid, David, Tortora, Giampaolo, Bracarda, Sergio, Necchi, Andrea, Massari, Francesco, Osawa, Takahiro, Shinohara, Nobuo, Fukuta, Fumimasa, Obara, Wataru, Tomita, Yoshihiko, Kawai, Koji, Matsubara, Nobuaki, Oyama, Masafumi, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Inokuchi, Junichi, Yokomizo, Akira, Lee, Jae-Lyun, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Flores, Claudia Lorena Urzua, Blaisse, Reinoud J B, van der Heijden, Michiel S, de Wit, Ronald, Aarts, Maureen J B, Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Safina, Sufia Z, Alekseev, Boris, Semenov, Andrey, Fomkin, Roman, Del Muro, F Xavier García, Lin, Chien-Liang, Yeh, Su-Peng, Çiçin, Irfan, Harputluoglu, Hakan, Erman, Mustafa, Golovko, Yurii, Bondarenko, Igor, Powles, Thomas, Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Drakaki, Alexandra, Petrylak, Daniel, Schwarz, James, Percent, Ivor, Hainsworth, John, Herms, Benjamin, Tagawa, Scott, Vaishampayan, Ulka

Volltext

Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 t... von Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R, Williams, Scott G, Martin, Andrew J, Davis, Ian D

Volltext

Sequential 177LuLu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase... von Azad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S

Volltext

177LuLu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial von Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, Yip, Sonia, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S, McJannett, Margaret, Martin, Andrew James, Stockler, Martin R, Davis, Ian D

Volltext

Changing Management and Survival in Patients With Stage IV Colorectal Cancer von Platell, Cameron, Ng, Siobhan, OʼBichere, Austin, Tebbutt, Niall

Volltext

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, pha... von Azad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S, Akhurst, T, Alipour, R, Au, L, Banks, P, Emerson, B, Hussain, N, Haskali, M, Lewin, J, Linklater, R, Kostos, L, Kashyap, R, Krishanth, P, Kong, G, Kumar, A, Murphy, D, Roselt, P, Sandhu, S, Scalzo, M, Tran, B, Wallace, R, Spain, L, Bourke, H, Milton, A, Russo, D, Bills, M, Chew, C, Hsieh, W, Crouch, B, Smyth, D, Pandelus, S, Lam, H, Gan, C, Goh, J, Scott, A, Hafeez, U, Ackermann, U, Young, K, Poon, A, Pathmaraj, K, Schembri, G, Roach, P, Bailey, D, Hung, T, Asad, A, Hagan, T, Watts, J, Campbell, E, Chua, W, Pal, A, Crumbaker, M, Nguyen, A, Yam, A, Chen, J, Ardolino, L, Kongrak, K, Ratnayake, L

Volltext

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone von RYAN, Charles J, ROSENTHAL, Mark, MIN ZHU, RUI TANG, OLINER, KellyS, YIZHOUJIANG, LOH, Elwyn, DUBEY, Sarita, GERRITSEN, Winald R, NG, Siobhan, ALUMKAL, Joshi, PICUS, Joel, GRAVIS, Gwenaëlle, FIZAZI, Karim, FORGET, Frédéric, MACHIELS, Jean-Pascal, SRINIVAS, Sandy

Volltext

Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZU... von Weickhardt, Andrew James, Foroudi, Farshad, Lawrentschuk, Nathan, Galleta, Laura, Seegum, Amanda, Herschtal, Alan, Link, Emma, McJannett, Margaret Mary, Liow, Elizabeth Chien Hern, Grimison, Peter S., Zhang, Alison Yan, Patanjali, NItya, Ng, Siobhan, Goodwin, Robert, Tang, Colin, Chen, Colin, Hovey, Elizabeth J., Hruby, George, Guminski, Alexander David, Davis, Ian D.

Volltext

Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer von Jiang, Di Maria, Parshad, Shruti, Zhan, Luna, Sim, Hao-Wen, Siu, Lillian L, Liu, Geoffrey, Shapiro, Jeremy D, Price, Timothy J, Jonker, Derek J, Karapetis, Christos S, Strickland, Andrew H, Zhang, Wenjiang, Jeffery, Mark, Tu, Dongsheng, Ng, Siobhan, Sabesan, Sabe, Shannon, Jenny, Townsend, Amanda, O'Callaghan, Chris J, Chen, Eric X

Volltext

Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer von Gulley, James L., Borre, Michael, Vogelzang, Nicholas J., Ng, Siobhan, Agarwal, Neeraj, Parker, Chris C., Pook, David William, Rathenborg, Per, Flaig, Thomas W., Carles, Joan, Shore, Neal D., Chen, Liddy, Heery, Christopher Ryan, Gerritsen, Winald R., Priou, Frank, Kantoff, Philip W.

Volltext